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major bleeding events (MBE) and clinically relevant non-
major bleeding events as bleeding outcomes, while a nar-
row definition included just MBE. The pooled dataset 
totalled 5107 patients from RE-COVER/RE-COVER II and 
2856 patients from RE-MEDY. When NCB was narrowly 
defined, NCB was similar between DE and warfarin. When 
broadly defined, NCB was superior with DE vs. warfarin 
[RE-COVER/RE-COVER II, hazard ratio (HR) 0.80; 95% 
confidence interval (CI), 0.68–0.95 and RE-MEDY, HR 
0.73; 95% CI 0.59–0.91]. These findings were unaffected 
by warfarin time in therapeutic range. The NCB of DE was 
similar or superior to warfarin, depending on the NCB defi-
nition used, regardless of the quality of INR control.
Keywords Venous thromboembolism · Warfarin · 
Dabigatran etexilate · Anticoagulant
Introduction
The direct oral anticoagulants (DOACs) are effective and 
usually well tolerated for treating venous thromboembolism 
(VTE) [1–7]. In pooled analyses from the RE-COVER® 
and RE-COVER™ II trials in patients with acute VTE, 
dabigatran etexilate (DE) at a fixed dose of 150 mg twice 
daily was as effective as warfarin [dose adjusted to achieve 
international normalized ratio (INR) between 2 and 3] for 
the treatment of acute VTE. For prevention of recurrent 
VTE, DE was associated with a significantly lower risk of 
clinically relevant, major or non-major, bleeding and of any 
bleeding events [6]. In the RE-MEDY™ trial of extended 
anticoagulation, DE was non-inferior to warfarin for the 
prevention of recurrent VTE, with a significantly lower risk 
of major or clinically relevant non-major bleeding [8].
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The benefit–risk balance of DE compared with war-
farin in VTE treatment and prevention of recurrence 
can be further understood by assessing the net clinical 
benefit (NCB) [9]. NCB weighs potential benefits (e.g., 
reduced risk of VTE or stroke) vs. potential harm (e.g., 
risk of bleeding). Thus, NCB quantifies both clinical effi-
cacy and safety outcomes. NCB is particularly useful in 
the assessment of multiple endpoints affecting mortality 
and morbidity [e.g., VTE, myocardial infarction (MI), 
stroke, major bleeding events (MBEs), clinically rel-
evant non-major bleeding events (CRNMBEs)] and for 
facilitating the comparison of the benefit–risk balance of 
anticoagulants.
The effectiveness and safety of warfarin depends on the 
time in therapeutic range (TTR) with an INR between 2.0 
and 3.0 [10]. Analysis of the NCB of dabigatran compared 
with that of warfarin at high TTRs will determine whether 
the comparative NCB is affected when INR is tightly 
controlled.
Post-hoc analyses were performed on pooled data from 
RE-COVER and RE-COVER II, as well as data from RE-
MEDY, to compare the NCB of DE with that of warfarin 
overall, and in relation to mean TTR for warfarin at each 
center (cTTR). Broad and narrow definitions of NCB were 
used: MBEs plus CRNMBEs as bleeding outcomes and 
MBEs as the only bleeding outcome, respectively.
Methods
Study population and trial design
The study designs, populations and outcomes of the RE-
COVER, RE-COVER II, and RE-MEDY trials have been 
published [5, 6, 8]. In all three trials, patients aged ≥18 
years with objectively confirmed symptomatic proximal 
deep vein thrombosis or pulmonary embolism were eligi-
ble for inclusion.
In RE-COVER and RE-COVER II, patients were ran-
domized to warfarin or warfarin–placebo plus parenteral 
anticoagulation for ≥5 days until the INR was ≥2 on two 
consecutive measurements. Parenteral therapy was then 
discontinued and patients continued warfarin (therapeutic 
INR range 2.0–3.0) or received DE 150  mg twice daily 
for 6 months (double-dummy treatment period).
In RE-MEDY, patients who had been treated for 3–12 
months with an approved anticoagulant (or were par-
ticipating in RE-COVER or RE-COVER II) were rand-
omized to DE 150 mg twice daily or warfarin (INR range 
2.0–3.0) for 6–36 months.
Table 1  Characteristics of patients receiving dabigatran or warfarin in RE-COVER/RE-COVER II pooled data and RE-MEDY
DVT deep vein thrombosis, PE pulmonary embolism, SD standard deviation
a REMEDY included 567 patients in the dabigatran group, and 606 patients in the warfarin group, that rolled over from RE-COVER and RE-
COVER II
b Results of objective testing for initial symptomatic DVT/PE performed locally. If a patient had more than one event, the last event prior to rand-
omization was classified as the qualifying event
c These were diagnosed with DVT or PE initially but refuted on subsequent local examination
Including  CRNMBEa Excluding  CRNMBEa
Dabigatran (n = 2553) Warfarin (n = 2554) Dabigatran (n = 1430) Warfarin (n = 1426)
Age, years, mean ± SD 54.8 ± 16.0 54.7 ± 16.2 55.4 ± 15.0 53.9 ± 15.3
Female sex, n (%) 1033 (40.5) 1033 (40.4) 559 (39.1) 555 (38.9)
Race or ethnic group, n (%)
 White 2206 (86.4) 2193 (85.9) 1288 (90.1) 1284 (90.0)
 Black 54 (2.1) 51 (2.0) 29 (2.0) 28 (2.0)
 Asian 292 (11.4) 310 (12.1) 113 (7.9) 114 (8.0)
Missing 1 (0.0) 0 (0.0)
Weight, kg, mean ± SD 84.3 ± 19.4 83.6 ± 19.0 86.1 ± 19.3 86.0 ± 18.9
Estimated creatinine clearance, 
ml/min, mean ± SD
107.0 ± 42.2 105.8 ± 40.5 104.2 ± 38.6 106.6 ± 37.9
Type of qualifying  eventb, n (%)
 DVT only 1755 (68.7) 1744 (68.3) 938 (65.6) 922 (64.7)
 PE only 569 (22.3) 567 (22.2) 324 (22.7) 335 (23.5)
 Both DVT and PE 226 (8.9) 240 (9.4) 167 (11.7) 168 (11.8)
 Neither DVT nor  PEc 3 (0.1) 3 (0.1) 1 (0.1) 1 (0.1)
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Study outcomes
For this post-hoc analysis, NCB was evaluated as the com-
posite of cardiovascular endpoints (the components being 
non-fatal events of recurrent VTE, MI, stroke or systemic 
embolism), all-cause death, and bleeding outcomes, which 
were all weighted equally. The bleeding outcomes either 
included MBEs alone (narrow definition of NCB) or MBEs 
plus CRNMBEs (broad definition of NCB). MBEs and 
CRNMBEs were defined according to the International 
Society on Thrombosis and Haemostasis criteria (MBEs) 
[11], and as previously defined for the phase 3 dabigatran 
studies (CRNMBEs) [6]. All events were evaluated from 
the beginning of the parenteral phase of anticoagulation 
treatment until the end of the post-treatment period (RE-
COVER and RE-COVER II) or from randomization to the 
end of the planned treatment period (RE-MEDY).
Statistical analyses
Outcomes were analyzed with a Cox proportional hazards 
model. Statistical analyses were performed with  SAS® ver-
sion 9.2 (Cary, NC, USA).
Results
Population
The pooled dataset from RE-COVER and RE-COVER 
II included 2553 patients randomized to DE and 2554 
patients randomized to warfarin [6]. The RE-MEDY data-
set consisted of 1430 and 1426 patients randomized to DE 
and warfarin, respectively [8]. Patient characteristics were 
generally similar between DE and warfarin groups in the 
pooled RE-COVER/RE-COVER II dataset and in RE-
MEDY (Table 1).
Net clinical benefit
When NCB was defined to include MBEs as the only 
bleeding outcome (narrow definition), NCB was similar 
between DE and warfarin (RE-COVER/RE-COVER II, HR 
1.02; 95% CI 0.81–1.27 and RE-MEDY, HR 1.05; 95% CI 
0.75–1.46) (Fig. 1a, b).
When MBEs plus CRNMBEs were included as bleed-
ing outcomes (broad definition), NCB was superior with 
DE compared with warfarin [RE-COVER/RE-COVER II, 
hazard ratio (HR) 0.80; 95% CI 0.68–0.95 and RE-MEDY, 
HR 0.73; 95% CI 0.59–0.91] (Fig. 1a, b).
In subgroups divided according to cTTR, the NCB (both 
definitions) with DE was similar to warfarin, regardless of 
warfarin cTTR in both the RE-COVER/RE-COVER II and 
the RE-MEDY analyses, with no trends observed, whether 
CRNMBEs were included as bleeding outcomes or not. 
This result was observed when centers were grouped into 
quintiles (Tables 2, 3) and when they were grouped into ter-
tiles (data not shown), according to their mean TTR (INR 
2–3) and overall number of patients. As only centers with 
≥1 patient with available TTR are included, these cTTR 
data are limited to 5055 patients vs. the 5107 patients in the 
study overall for the RE-COVER/RE-COVER II analysis, 
and 2813 patients vs. the 2856 patients in the study overall 
for the RE-MEDY analysis.
Discussion
Phase 3 trials have shown DE to be as effective as warfa-
rin for the treatment of acute VTE and for the extended 







































HR 0.80 (95% CI 0.68, 0.95)
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Fig. 1  Net clinical benefit for dabigatran vs. warfarin in a RE-
COVER/RE-COVER II pooled data and b RE-MEDY. *Non-fatal 
events of recurrent VTE, MI, stroke, or systemic embolism. CI con-
fidence interval, CRNMBE clinically relevant non-major bleeding 
event, HR hazard ratio, MBE major bleeding event, MI myocardial 
infarction, NCB net clinical benefit, VTE venous thromboembolism
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8]. Whereas clinical trials tend to treat benefits and risks 
as separate entities, evaluation of the NCB can provide a 
clearer representation of the benefit–risk balance of a treat-
ment overall by analyzing efficacy and safety as a collective 
outcome.
The inclusion of CRNMBEs in the evaluation of NCB 
provides a comprehensive reflection of anticoagulant safety 
outcomes encountered in real-world clinical practice [9]. 
This is because CRNMBEs, which include bleeding lead-
ing to hospitalization or requiring surgical treatment, could 
adversely affect prognosis and can also result in reduced 
patient adherence to, and persistence with, necessary anti-
coagulant therapy [12, 13].
Although NCBs of DE and warfarin were similar when 
the NCB included only MBEs as the bleeding outcome, 
the NCB of DE was superior to that of warfarin when 
CRNMBEs were also included in the calculation.
It was surprising that the analysis of NCB stratified by 
cTTR showed that quality of warfarin control did not influ-
ence the relative benefits of dabigatran and warfarin for the 
treatment and secondary prevention of VTE. This was true 
when either the broad or the narrow NCB definitions were 
used.
Study strengths and limitations
RE-COVER, RE-COVER II and RE-MEDY were ran-
domized, double-blind studies with central adjudication 
of outcome events. RE-MEDY is the only study so far of 
a DOAC with warfarin as the comparator in the extended 
treatment of VTE. The NCB definitions included clini-
cally relevant cardiovascular endpoints (including stroke 
and systemic embolism) and all-cause mortality, as well as 
bleeding.
One limitation is that the endpoints included in the NCB 
definition do not have an equal impact on morbidity and 
mortality, but were weighted equally in this analysis. Fur-
thermore, in analyses on the association of clinical effects 
of DE with quality of warfarin control (cTTR), limited data 
were presented, as these were dependent on the availability 
Table 2  Event rates for the 
composite cardiovascular 
endpoint including MBE and 
all death, with or without 
CRNMBE, stratified by 
center TTR in RE-COVER/
RE-COVER II
HR obtained from Cox Model with treatment, center TTR and treatment by center TTR interaction strati-
fied by study
CI confidence interval, CRNMBE clinically relevant non-major bleeding event, HR hazard ratio, INR inter-
national normalized ratio, TTR time in therapeutic range
*P value for treatment by center TTR interaction: 0.0815
**P value for treatment by center TTR interaction: 0.3896
a Centers grouped into five categories according to their mean TTR (INR 2–3) and overall number of 
patients (quintiles). Only centers with at least one patient with available TTR (INR 2–3) were included
Center TTR  categorya Including CRNMBE* Excluding CRNMBE**
Dabigatran Warfarin Dabigatran Warfarin
<47.1
 Patients, N 516 531 516 531
 Event rate, % 11.0 16.2 8.3 9.0
 HR vs. warfarin (95% CI) 0.66 (0.47, 0.92) 0.92 (0.61, 1.39)
47.1 to <57.7
 Patients, N 450 489 450 489
 Event rate, % 8.4 9.6 5.3 4.3
 HR vs. warfarin (95% CI) 0.86 (0.56, 1.31) 1.24 (0.69, 2.22)
57.7 to <61.9
 Patients, N 555 530 555 530
 Event rate, % 8.5 10.9 4.1 5.8
 HR vs. warfarin (95% CI) 0.76 (0.52, 1.12) 0.71 (0.41, 1.21)
61.9 to <68.0
 Patients, N 481 492 481 492
 Event rate, % 9.4 13.4 5.8 5.5
 HR vs. warfarin (95% CI) 0.67 (0.46, 0.98) 1.05 (0.62, 1.78)
≥68.0
 Patients, N 501 510 501 510
 Event rate, % 12.6 10.0 7.0 4.9
 HR vs. warfarin (95% CI) 1.27 (0.88, 1.84) 1.43 (0.86, 2.39)
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of patient INR measurements. Finally, this was a post-hoc 
analysis.
These analyses of safety and efficacy data support previ-
ous assessments of the benefit–risk balance of DE vs. war-
farin [5, 6, 8].
Conclusion
The NCB of DE is superior to that of warfarin when the 
NCB definition includes MBEs plus CRNMBEs (typical of 
the safety outcomes arising in real-world clinical practice). 
This applies to both the initial treatment and the extended 
treatment of VTE. The NCB of DE is similar to warfarin 
when NCB includes only MBEs as the bleeding outcome.
These results indicate a positive impact of DE, in com-
parison with warfarin, on the clinical outcome of patients 
treated for acute VTE or for secondary VTE prevention in 
clinical practice settings, regardless of the quality of INR 
control.
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